LOGIN  |  REGISTER
Terns Pharmaceuticals

Latest Medical Device Stock News

Merit Medical Systems Announces FDA Approval of the WRAPSODY Cell-Impermeable Endoprosthesis

December 20
Last Trade: 98.22 1.95 2.03

Unique cell-impermeable1 design extends life-saving treatment for dialysis patients Merit to host a WRAPSODY informational call on January 28, 2025 SOUTH JORDAN, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that the WRAPSODY® Cell-Impermeable Endoprosthesis has received premarket approval from the US Food and...Read more


Aethlon Medical Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu

December 20
Last Trade: 0.60 0.16 37.75

SAN DIEGO, Dec. 20, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided a statement of its investigational medical device with respect to H5N1 avian influenza "Bird Flu." Aethlon has recently received a number of inquiries regarding the potential utility of its Hemopurifier device in the...Read more


Zimmer Biomet to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 20
Last Trade: 107.12 1.31 1.24

WARSAW, Ind., Dec. 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 8:15 a.m. PT (11:15 a.m. ET). A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The...Read more


Bruker Announces 1.2 GHz NMR Spectrometer at Swiss High-field NMR Facility

December 20
Last Trade: 57.00 1.71 3.09

State-of-the-art instrument enhances research in structural biology and protein analysis ZÜRICH / Dec 20, 2024 / Business Wire / Bruker announces the acceptance of a 1.2 GHz Ascend™ Nuclear Magnetic Resonance (NMR) spectrometer at the Swiss High-field NMR Facility, operated jointly by the University of Basel, ETH Zürich, and the University of Zürich. This state-of-the-art instrument will significantly enhance the research capabilities...Read more


AVITA Medical Announces FDA 510(k) Clearance for Cohealyx, Expanding its Addressable Market

December 19
Last Trade: 11.77 0.29 2.53

New collagen-based dermal matrix designed for tissue generation, complementary to RECELL and PermeaDerm Cohealyx expected to triple AVITA Medical’s addressable market in burns VALENCIA, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S....Read more


Modular Medical Announces Licensing and Partnership Agreement With Nudge BG

December 19
Last Trade: 1.39 -0.04 -2.80

Modular Medical will collaborate with Nudge BG to bring to market an adaptive full closed loop Automated Insulin Delivery system that does not require mealtime announcements Effort will be led be Nudge BG founder and noted AID expert, Lane Desborough SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 19, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first...Read more


OraSure Technologies Acquires Sherlock Biosciences

December 19
Last Trade: 3.64 -0.15 -3.96

BETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers. This acquisition expands OraSure’s innovation pipeline with the addition of Sherlock’s...Read more


Smith+Nephew introduces CORIOGRAPH™ Pre-Op Planning and Modeling Services for Total Hip Arthroplasty

December 19
Last Trade: 24.66 -0.13 -0.52

Latest expansion to the CORI◊ Surgical System portfolio provides a personalized solution for patients and surgeons Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces its CORIOGRAPH Pre-Op Planning and Modeling Services is now cleared for total hip arthroplasty (THA) by the United States Food and Drug Administration. Exclusively for users of the CORI Surgical System, this innovative planning...Read more


Envoy Medical Names Seven Investigational Sites for Participation in Its Pivotal Clinical Study

December 19
Last Trade: 1.64 -0.20 -10.87

Initial patient enrollment anticipated during first quarter of 2025 White Bear Lake, Minnesota--(Newsfile Corp. - December 19, 2024) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company, today announces it has selected seven study sites for participation in its pivotal clinical trial to investigate its fully implanted Acclaim® cochlear implant (Acclaim CI). Initial patient enrollment is anticipated to...Read more


Vivani Medical Announces Initiation of First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in Australia

December 19
Last Trade: 1.18 0.00 0.00

NPM-115 clinical program utilizes a miniature, GLP-1 (exenatide) implant designed to provide comparable efficacy to semaglutide, with twice-yearly administration Study represents the first clinical application of NanoPortal™, the Company’s proprietary drug implant platform technology ALAMEDA, Calif. / Dec 19, 2024 / Business Wire / Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative biopharmaceutical company...Read more


IRadimed to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 19
Last Trade: 54.65 1.30 2.44

WINTER SPRINGS, Fla., Dec. 19, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (“MRI”) compatible medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system announced today that Roger Susi, Chief Executive Officer and Jack Glenn, Chief Financial Officer, will present at the 43rd Annual J.P. Morgan Healthcare...Read more


Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters

December 19
Last Trade: 0.78 0.01 1.70

Partnership launched with fully-contracted #CheckYourFoodTube Precancer Testing Event for Tuscaloosa firefighters NEW YORK, Dec. 19, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has entered into a strategic partnership with VITALExam LLC...Read more


Getinge and 908 Devices Partner to Enhance Bioreactor Capabilities for Continuous Monitoring of Key Cell Culture Parameters

December 19
Last Trade: 2.06 0.12 6.19

BOSTON / Dec 19, 2024 / Business Wire / Today, 908 Devices Inc. (Nasdaq: MASS) and Getinge announce their collaboration to integrate Getinge’s bioreactors with 908 Devices’ MAVEN for automated control of glucose and lactate levels in cell cultures. The combined solution will help scientists measure critical process parameters in bioreactors, offering continuous, real-time analysis without the need for manual sampling. In the field of...Read more


Conavi Medical Reports Fiscal 2024 Financial Results and Operational Highlights

December 19
Last Trade: 0.63 0.00 0.00

Completed US$7.7 million financing and reverse takeover to take Company public Chinese partner achieved regulatory approval, setting stage for royalty stream and triggering US$5.9 million payment, enabling Company to fully repay debt to that partner U.S. FDA submission of Novasight 3.0 system on track for calendar 2025 TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“Conavi Medical” or the “Company”),...Read more


Baxter to Present at 43rd Annual J.P. Morgan Healthcare Conference

December 18
Last Trade: 29.50 0.60 2.08

DEERFIELD, Ill. / Dec 18, 2024 / Business Wire / Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. José (Joe) E. Almeida, Baxter's chair, president and chief executive officer, is scheduled to present at 10:30 a.m. Pacific Time. The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for...Read more


AVITA Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 18
Last Trade: 11.77 0.29 2.53

VALENCIA, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 9:00 a.m. Pacific Time. A live audio webcast of the...Read more


NeuroPace to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 18
Last Trade: 11.53 0.39 3.50

MOUNTAIN VIEW, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference at 4:30pm PT (7:30pm ET) on Wednesday, January 15, 2025, in San Francisco, CA. Management will also host investor meetings during the conference. The...Read more


Iridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management

December 18
Last Trade: 1.64 -0.07 -4.09

MOUNTAIN VIEW, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the publication of a landmark peer-reviewed study in Ophthalmology Therapy. This study highlights the sustained safety and efficacy of MicroPulse Transscleral Laser Therapy (TLT)...Read more


GRAIL to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 18
Last Trade: 18.35 1.21 7.06

MENLO PARK, Calif., Dec. 18, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15 at 9:00 a.m. PT.  Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at...Read more


RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression

December 18
Last Trade: 47.59 0.10 0.21

Results published in two articles in Brain Stimulation LONDON / Dec 18, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Brain Stimulation has published two pivotal articles chronicling the unipolar cohort data set for the RECOVER clinical study. The researchers evaluated the safety and efficacy of LivaNova’s VNS Therapy™ System and its effectiveness on...Read more


Intelligent Bio Solutions Announces 510(k) Submission to US FDA for Fingerprint Sweat-Based Drug Screening Technology

December 18
Last Trade: 1.30 0.03 2.36

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the submission of its 510(k) premarket notification to the US Food and Drug Administration (FDA) for clearance following FDA review of its Intelligent Fingerprinting Drug Screening System (the "System"), an...Read more


Hologic to Contribute to H5N1 Bird Flu Test Development via Agreement Issued by CDC

December 18
Last Trade: 71.65 0.89 1.26

MARLBOROUGH, Mass. / Dec 18, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) today announced that it has entered into an agreement with the Centers for Disease Control and Prevention (CDC) to develop analyte specific reagents (ASRs) — the “active ingredients” of laboratory-developed tests used to identify specific diseases or conditions — that would aid in the detection of H5N1 bird flu. H5N1 bird flu, also known as avian influenza A...Read more


VentriPoint Diagnostics and ASCEND Cardiovascular sign Term Sheet for integration of VMS+ into ASCEND's Gen3Echo(TM) platform

December 18
Last Trade: 0.10 0.00 0.00

Toronto, Ontario – TheNewswire - December 18, 2024 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTCQB:VPTDF) is pleased to announce Ventripoint and ASCEND Cardiovascular, a leading provider of cardiovascular IT solutions, have signed a term sheet defining the general terms and conditions for a non-exclusive license to Ventripoint’s VMS+ proprietary technology.  The two parties expect to execute the...Read more


Accuray: New Data Indicates the CyberKnife® System Can Provide a Safe and Effective Treatment Option to Control Brainstem Metastases, an Extremely Challenging Location to Treat

December 18
Last Trade: 1.85 0.06 3.35

Study Builds on Extensive Published Literature Highlighting the Benefits of the CyberKnife System in the Treatment of a Wide Range of Neurological Indications MADISON, Wis., Dec. 18, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today an international retrospective multicenter analysis found that radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT), delivered with the CyberKnife®...Read more


Therma Bright Signs LOI For U.S. Distribution Network Expansion For Venowave With DME Authority

December 18
Last Trade: 0.03 0.00 0.00

Initiative Includes Milestone-Based Inventory Purchase Commitments During Q1 and Q2, 2025 Toronto, Ontario--(Newsfile Corp. - December 18, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce the Company has signed a letter of intent (LOI) for a Venowave distribution...Read more


CooperCompanies to Present at the J.P. Morgan Healthcare Conference

December 17
Last Trade: 93.44 1.51 1.64

SAN RAMON, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, today announced it will participate at the J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025. Al White, President and CEO, will represent the Company in a session scheduled to begin at 6:00 PM ET. A live and archived webcast of this event, where applicable, will be available by accessing the CooperCompanies’...Read more


electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness

December 17
Last Trade: 15.27 0.75 5.17

The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector Company to discuss acquisition and host investor Q&A in a webcast today at 4:30 p.m. EST ROCKAWAY, N.J., Dec. 17, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (“ECOR,” “electroCore,” or the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today it has entered...Read more


Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery

December 17
Last Trade: 17.98 0.19 1.07

Preclinical data demonstrates advantages of the nano-PFA Cardiac Surgical System over radio frequency technology for ablation of cardiac tissue MIAMI / Dec 17, 2024 / Business Wire / Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced a new publication in the Journal of Thoracic and Cardiovascular Surgery. This...Read more


Abbott Announces First-in-World Leadless Pacing Procedures in the Left Bundle Branch Area of the Heart

December 17
Last Trade: 114.23 1.81 1.61

Abbott's investigational AVEIR™ Conduction System Pacing (CSP) leadless pacemaker system is specifically designed to deliver pacing to the left bundle branch area, activating the heart's natural conduction system The device has received U.S. Food and Drug Administration Breakthrough Device Designation, which expedites the review of innovative technologies By creating a new pacing approach for the left bundle branch area of the heart,...Read more


Quanterix Expands Capabilities with Strategic Acquisition of EMISSION

December 17
Last Trade: 10.50 0.51 5.11

Builds technology capabilities through vertical integration of proprietary bead technology and drives OEM business BILLERICA, Mass. / Dec 17, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the acquisition of EMISSION iNC. (“EMISSION”). Quanterix expects the transaction will close in January...Read more


Becton Dickinson and Babson Diagnostics Launch Innovative Fingertip Blood Testing to Health Care Organizations

December 17
Last Trade: 227.68 3.85 1.72

FRANKLIN LAKES, N.J. and AUSTIN, Texas, Dec. 17, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Babson Diagnostics, a science-first health care technology company, today announced an expansion of fingertip blood collection and testing technologies for use by U.S. health systems and other large provider networks in settings like urgent cares, doctor offices and other...Read more


VentriPoint Diagnostics Announces Closing of First Tranche of Amended Non-Brokered Convertible Debenture Private Placement

December 17
Last Trade: 0.10 0.00 0.00

Toronto, Ontario, December 17, 2024 – TheNewswire - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”, TSXV:VPT) announces that it has closed the first tranche of its previously announced (see November 6, 2024 and December 9, 2024 press releases) amended non-brokered private placement of unsecured convertible debentures (“Debentures”). Ventripoint has issued an aggregate of $341,000 principal amount of Debentures with an...Read more


NeuroOne Medical Technologies Product Revenue Increases 77% to $3.5 Million in Fiscal 2024: Expects Product Revenue to Increase at Least 132% to at Least $8 Million in Fiscal 2025

December 17
Last Trade: 0.76 0.00 0.00

Company’s Exclusive Distribution Agreement with Zimmer Biomet included $3.0 Million Upfront Payment: Expected to Drive Revenue and Expand Margins Significantly EDEN PRAIRIE, Minn., Dec. 17, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has reported...Read more


Quipt Home Medical Reports Fourth Quarter and Fiscal Year 2024 Financial Results

December 16
Last Trade: 2.49 0.08 3.32

Posts Strong Adjusted EBITDA Margin‎1 ‎for Fiscal Year 2024 and Returns to Positive Sequential Growth in Fiscal Q4 2024 CINCINNATI, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its fourth quarter and fiscal year 2024 financial results and operational highlights....Read more


Smith+Nephew expands AETOS™ Shoulder System with new stemless option for anatomic shoulder arthroplasty

December 16
Last Trade: 24.66 -0.13 -0.52

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has received 510(k) clearance from the United States Food & Drug Administration for a stemless anatomic total shoulder for the AETOS Shoulder System (AETOS Stemless).  AETOS Stemless addresses the growing demand for anatomic total shoulder replacement with a small operating room footprint allowing for an efficient procedure.1 It is...Read more


Envoy Medical Receives Additional Patent Protection for its Innovative Approach to Hearing Loss

December 16
Last Trade: 1.64 -0.20 -10.87

WHITE BEAR LAKE, Minnesota , Dec. 16, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (NASDAQ: “COCH”), a hearing health company focused on providing hearing loss suffers with innovative solutions today announces four new patents. The US Patent & Trademark Office issued Envoy Medical Corporation US Pat. No. 12,151,102 on November 25, 2024. The title of the patent is Combination Hearing Aid and Cochlear Implant System....Read more


enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

December 16
Last Trade: 2.49 -0.04 -1.58

Successful Completion of All Planned Implants in GLP Study enVVe Delivery System Demonstrates Consistent Performance Company Maintains Timeline for IDE Application Submission by Mid-2025, Pending GLP Study Results IRVINE, CA / ACCESSWIRE / December 16, 2024 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the...Read more


Data on IceCure Medical's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting

December 16
Last Trade: 1.12 -0.04 -3.04

ICE3 trial results presented by ICE3 Co-Principal Investigator Dr. Kenneth Tomkovich FDA Advisory Panel voted in favor of IceCure's ProSense® cryoablation benefit-risk profile in early-stage low risk breast cancer in Nov. 2025 FDA's marketing authorization decision expected in Q1, 2025  CAESAREA, Israel, Dec. 16, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"),...Read more


Treace Medical Concepts Announces First Surgical Cases Utilizing the SpeedPlate™ MicroQuad™ Implant

December 16
Last Trade: 6.96 0.06 0.87

PONTE VEDRA, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the successful completion of the first cases utilizing SpeedPlate™ MicroQuad™ implants. The MicroQuad™...Read more


Butterfly Network to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 16
Last Trade: 3.09 0.12 4.04

NEW YORK & BURLINGTON, Mass. / Dec 16, 2024 / Business Wire / Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced that it will participate at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025 at the Westin St. Francis in San Francisco, California. Joseph DeVivo, President, Chief...Read more


Varex Imaging Announces Private Offering of $125 Million of Senior Secured Notes

December 16
Last Trade: 14.16 -0.22 -1.53

SALT LAKE CITY / Dec 16, 2024 / Business Wire / Varex Imaging Corporation (Nasdaq: VREX) today announced it has commenced a private offering (the “Offering”), subject to market and other conditions, of $125 million aggregate principal amount of its 7.875% senior secured notes due October 15, 2027 (the “notes”). The notes offered hereby will be issued as “Additional Notes” and will constitute a further issuance of our 7.875% senior secured...Read more


Anteris Technologies Global Announces Closing of $88.8 Million U.S. Initial Public Offering

December 16
Last Trade: 0 0.00 0.00

BRISBANE, Australia & EAGAN, Minn. / Dec 16, 2024 / Business Wire / Anteris Technologies Global Corp. (“ATGC” or “Anteris”) is pleased to announce the closing of its initial public offering of 14,800,000 shares of its common stock (the “Common Stock”) in the U.S. at a price of $6.00 per share (the “Offering”). An additional 2,220,000 shares of Common Stock are issuable pursuant to the underwriters’ option to purchase additional shares...Read more


LeMaitre Vascular Announces Proposed Convertible Senior Notes Offering

December 16
Last Trade: 92.12 -0.13 -0.14

BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (“LeMaitre”) (Nasdaq: LMAT) today announced its intention to offer, subject to market and other conditions, $150,000,000 aggregate principal amount of Convertible Senior Notes due 2030 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). LeMaitre also...Read more


BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

December 16
Last Trade: 27.39 1.28 4.90

BOTHELL, Wash., Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation (Nasdaq: RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025....Read more


HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results

December 16
Last Trade: 3.82 0.40 11.70

Southlake, TX, Dec. 16, 2024 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the second quarter fiscal 2025 ended October 31, 2024 and provided a business update. Second Fiscal Quarter 2025...Read more


QHSLab and South Dakota State University Celebrate NSF Invitation to Submit STTR Application for AIR-GUIDDE Technology

December 13
Last Trade: 0.27 0.07 33.93

NSF Recognition: A Testament to Innovation Driving Strategic Growth and Shareholder Value WEST PALM BEACH, FL, Dec. 13, 2024 (GLOBE NEWSWIRE) -- QHSLab Inc. ("the Company") (OTCQB: USAQ), a leading provider of digital healthcare solutions and diagnostic technologies, is thrilled to announce that it has been invited by the prestigious National Science Foundation (NSF) to submit a full Phase I application for the development of...Read more


Zimmer Biomet Receives FDA Clearance for OsseoFit™ Stemless Shoulder System for Total Shoulder Replacement

December 13
Last Trade: 107.12 1.31 1.24

New Anatomically Shaped Asymmetric Stemless Design for Total Shoulder Replacement WARSAW, Ind., Dec. 13, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the OsseoFit™ Stemless Shoulder System for total shoulder replacement. This innovative implant is designed to match the natural...Read more


Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England

December 13
Last Trade: 8.01 0.01 0.12

Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England First patients implanted with Genio at UCLH, London Mont-Saint-Guibert, Belgium – December 13, 2024, 8:05am CET / 2:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the...Read more


Zynex UCSF Study Results Demonstrate Laser Technology Benefits in Resolving Racial Bias of Current LED Pulse Oximeters

December 12
Last Trade: 8.25 -0.15 -1.79

ENGLEWOOD, Colo., Dec. 12, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced highlights from a recent study comparing its NiCO™ laser pulse oximeter to conventional LED pulse oximeters for the effects of skin...Read more


BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder

December 12
Last Trade: 9.24 0.28 3.12

BURLINGTON, Mass. and JERUSALEM, Dec. 12, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced recent positive pilot data from an independent, third-party study conducted at Stanford University evaluating an accelerated protocol using the Company’s Deep Transcranial Magnetic Stimulation (TMS) technology...Read more


Spectral AI Highlights Unprecedented Collaboration with National Leaders in Burn Care for DeepView™ System Training and Validation Studies

December 12
Last Trade: 1.89 0.01 0.53

DALLAS, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. FDA in 2018, that uses multi-spectral imaging and algorithms to predict burn healing potential, today announced that national leaders in burn care have dedicated more than an estimated 511 in-person days of physician engagement to...Read more


Electromedical Technologies Unveils Groundbreaking Details About the WellnessPro Infinity and Announces Production Timeline

December 11
Last Trade: 0 0.00 0.00

Electromedical Technologies is excited to share key updates on the WellnessPro Infinity, a revolutionary device redefining the standards of pain management and wellness technology. SCOTTSDALE, ARIZONA / ACCESSWIRE / December 11, 2024 / Electromedical Technologies, Inc. (OTC PINK:EMED) - Electromedical Technologies is excited to share key updates on the WellnessPro Infinity, a revolutionary device redefining the standards of pain...Read more


Nanalysis Scientific and The United States Pharmacopeia (USP) Co-Publish Study Demonstrating Efficacy of Benchtop NMR for Quality Control

December 11
Last Trade: 0.30 -0.01 -3.28

CALGARY, AB, Dec. 11, 2024 /CNW/ - Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), a leader in portable NMR instruments and MRI technology for industrial and research applications announces results of study by the United States Pharmacopeia (USP) concluding that benchtop NMR is efficacious for quality control of active pharmaceutical ingredients (API). "In the not-too-distant future, we expect...Read more


NanoVibronix Secures $12 Million Minimum Purchase Commitment for PainShield with Extension of Distribution Agreement

December 11
Last Trade: 0.62 0.04 6.04

Extends Relationship with Ultra Pain Products, Inc for Distribution of PainShield for Five Years ELMSFORD, N.Y. / Dec 11, 2024 / Business Wire / NanoVibronix, Inc., (NASDAQ: NAOV) (the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has renewed its exclusive distribution agreement with Ultra Pain...Read more


Baxter Announces Continued Growth of Pharmaceuticals Portfolio With Five Injectable Product Launches in the U.S.

December 11
Last Trade: 29.50 0.60 2.08

New launches reinforce Baxter’s leadership in bringing high-value, specialty injectable products to market to help address critical patient needs Products help support patient safety, simplify medication preparation and increase efficiencies for healthcare professionals Marks total of 10 launches1 for Baxter’s U.S. Pharmaceuticals portfolio in 2024 DEERFIELD, Ill. / Dec 11, 2024 / Business Wire / Baxter International Inc. (NYSE:BAX),...Read more


Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication

December 11
Last Trade: 0.78 0.01 1.70

Study demonstrates outstanding clinical utility including an exceptionally high 85% patient compliance with referral to confirmatory upper endoscopy following EsoGuard esophageal precancer testing NEW YORK, Dec. 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today...Read more


Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities

December 11
Last Trade: 18.14 0.19 1.06

VAUGHAN, Ontario / Dec 11, 2024 / Business Wire / Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that an affiliate has acquired Elios Vision, Inc., developer of the ELIOS™ procedure, the first clinically validated, minimally invasive glaucoma surgery (MIGS) procedure using an excimer laser. The acquisition unlocks new opportunities to...Read more


West Pharmaceutical Elects New Director to the Board

December 11
Last Trade: 331.40 4.39 1.34

EXTON, Pa., Dec. 11, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the Company's Board of Directors has elected Janet Haugen as its newest member. With the addition of Ms. Haugen, West's Board has 12 directors. Ms. Haugen, 66, is the former Chief Financial Officer of Unisys Corporation, a role she served...Read more


Paragon 28 Appoints Dave Demski to Board of Directors

December 11
Last Trade: 10.03 0.23 2.35

ENGLEWOOD, Colo. / Dec 11, 2024 / Business Wire / Paragon 28, Inc. (NYSE: FNA), (the “Company”) a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades of executive leadership experience. With the addition of Mr. Demski, the Company increased the...Read more


Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares

December 10
Last Trade: 7.25 -0.03 -0.41

TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of common shares (the “Common Shares”) at a public offering price of US$7.50 per Common Share. The underwriters elected to exercise the over-allotment option in full, resulting in an aggregate of 5,366,705 Common Shares...Read more


Tandem Diabetes Care t:slim X2 Insulin Pump Now Compatible with Dexcom G7 CGM in Canada

December 10
Last Trade: 35.91 2.64 7.94

MARKHAM, Ontario / Dec 10, 2024 / Business Wire / Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. today announced that following the recent authorization of sale by Health Canada, in-warranty t:slim X2™ insulin pump users can now access full compatibility with both the Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems. The t:slim X2 insulin pump with Control-IQ technology is the #1-rated automated insulin...Read more


Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions

December 10
Last Trade: 2.49 -0.06 -2.35

MARLBOROUGH, Mass. and FRANKFURT, Germany, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company, and NeraCare, a leading developer of laboratory tests for the prognosis of melanoma, today announced an exclusive global license agreement to develop and commercialize NeraCare’s Immunoprint test on Akoya's multiplexed immunofluorescent platform. Building on the research collaboration between...Read more


Microbot Medical Announces FDA Submission for the Commercialization of the LIBERTY® Endovascular Robotic System

December 10
Last Trade: 0.97 0.0005 0.05

FDA 510(k) Submission Follows the Successful Completion of the Pivotal Human Clinical Trial FDA 510(k) Clearance Anticipated During the Second Quarter of 2025 Company Preparing to Commence Commercialization Following FDA 510(k) Clearance BRAINTREE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative single use LIBERTY® Endovascular Robotic System, today announced that it has...Read more


Inspira Technologies Expands HYLA™ Blood Sensor Technology into Personalized Blood Lab Testing for Rapid Detection of Serious Medical Conditions

December 10
Last Trade: 0.90 -0.03 -3.52

RA'ANANA, Israel, Dec. 10, 2024 /PRNewswire/ -- Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN, IINNW), ("Inspira Technologies" or the "Company"), a groundbreaking life support technology company, revealed the expansion of its HYLA blood sensor technology ("HYLA") into an immediate personalized Blood Lab Test, aimed at performing real-time patient blood work for the rapid detection in minutes of the potential development of an...Read more


Alphatec to Present at the 2025 J.P. Morgan Healthcare Conference

December 9
Last Trade: 9.35 0.50 5.65

CARLSBAD, Calif. / Dec 09, 2024 / Business Wire / Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced today that management will present at the J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, CA, at 5:15pm PT on January 15, 2025. The webcast and the presentation materials will be available on the Investor...Read more


China's NMPA Approves EOM’s Coronary Imaging System Based on Conavi Medical’s IP

December 9
Last Trade: 0.63 0.00 0.00

Approval triggers fourth and final US$5.9 million milestone payment to Conavi Medical, which it will use to extinguish the promissory note owed by it to EOM  Conavi Medical eligible to receive future tiered royalty payments, ranging from 5.0%-10.0%, on net EOM coronary imaging system sales in China  TORONTO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“Conavi Medical” or the “Company”), a...Read more


Hologic: New Data To Be Presented at SABCS 2024 Investigates the Potential Role of the Breast Cancer Index® Test in Identifying Patients With Minimal Risk of Distant Recurrence

December 9
Last Trade: 71.65 0.89 1.26

Study Assesses Prognostic Value of BCI Testing and Its Potential in Supporting De-escalation of Primary Adjuvant Endocrine Therapy MARLBOROUGH, Mass. / Dec 09, 2024 / Business Wire / Four new studies regarding the Breast Cancer Index (BCI) test will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS). Among these studies, initial data will be premiered investigating the potential role of the BCI test to identify...Read more


Theralase Technologies Launches Three New Clinical Study Sites in USA

December 9
Last Trade: 0.25 -0.02 -7.41

Associated Medical Professionals of NY, Urology of Indiana and Central Ohio Urology Group are the latest three US-based study sites for clinical research of Theralase®'s bladder cancer treatment TORONTO, ON / ACCESSWIRE / December 9, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound...Read more


Senseonics Provides Update on Eversense 365 Launch

December 9
Last Trade: 0.46 0.02 4.07

GERMANTOWN, Md., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today provided commercial updates related to the Eversense® 365 launch. Eversense 365 Commercial Launch Update Launched Eversense 365 in October with global commercial...Read more


Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis

December 9
Last Trade: 28.48 0.51 1.82

ATLANTA, Dec. 9, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted a Humanitarian Device Exemption (HDE) for use of the AMDS Hybrid Prosthesis ("AMDS") in acute DeBakey Type I dissections in the presence of malperfusion. The AMDS is the world's first aortic arch remodeling device for use in...Read more


Spectral AI Incorporates Frontline Feedback into Improved Software Release for Enhanced Diagnostic Precision

December 9
Last Trade: 1.89 0.01 0.53

DALLAS, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on revolutionizing medical diagnostics to enable faster, more accurate treatment decisions in wound care, today announced the completion of enhancements to its technical file to support significant software updates for its DeepView SnapShot® M and DeepView AI-Burn® system in the UK. These...Read more


Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns

December 9
Last Trade: 144.46 -2.08 -1.42

WALTHAM, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the launch of AVIPure® dsRNA Clear OPUS® columns, a groundbreaking solution designed to simplify and enhance the production of mRNA therapeutics and vaccines. This novel affinity chromatography offering marries Repligen’s breakthrough dsRNA purification resin with its...Read more


Stereotaxis: Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China’s NMPA

December 9
Last Trade: 2.35 0.13 5.86

ST. LOUIS and SHANGHAI, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai MicroPort EP Medtech Co., Ltd. (688351.SH, “MicroPort EP”), today announced that the Magbot™ Magnetic Navigation Ablation Catheter has received regulatory approval from China’s National Medical Products Administration (NMPA). The Magbot™ Catheter is a single-use magnetic saline-irrigated radiofrequency ablation catheter designed and developed...Read more


InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)

December 9
Last Trade: 3.00 0.02 0.67

MIAMI, Dec. 09, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the first patient has been enrolled in the company’s CGUARDIANS II clinical trial evaluating its CGuard Prime Carotid Stent System in patients undergoing carotid artery stenting via the Transcarotid Artery Revascularization (TCAR) approach. The patient...Read more


AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation

December 9
Last Trade: 8.89 0.31 3.61

LATHAM, N.Y. / Dec 09, 2024 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for the NanoKnife System for prostate tissue ablation. The Company received...Read more


CytoSorbents Announces Rights Offering

December 9
Last Trade: 0.92 0.04 3.99

PRINCETON, N.J., Dec. 09, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the details of its anticipated Rights Offering. Investors who hold or have bought CTSO stock at the close of Nasdaq trading on Friday, December 13, 2024 will be deemed stockholders of record on December...Read more


Martin Madaus Elected to Hologic Board of Directors

December 9
Last Trade: 71.65 0.89 1.26

MARLBOROUGH, Mass. / Dec 09, 2024 / Business Wire / Hologic, Inc. (Nasdaq: HOLX) announced today that Martin Madaus has been elected to the Company’s Board of Directors, effective December 6, 2024. Dr. Madaus was also appointed to the Compensation Committee and the Nominating and Corporate Governance Committee effective December 6, 2024. Dr. Madaus, who has more than 30 years of diagnostics and life sciences industry experience, currently...Read more


Intuitive Surgical: Meta-analysis published in Annals of Surgery shows benefits of da Vinci surgery across seven oncologic procedures compared to laparoscopic and open

December 5
Last Trade: 524.43 0.52 0.10

Analysis included 230 studies—a mix of randomized, prospective, and database research SUNNYVALE, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) --The peer-reviewed Annals of Surgery published a meta-analysis of 30-day surgical outcomes across seven oncological surgical procedures, comparing robotic, laparoscopic, and open surgical approaches. The study covered a 12-year timeframe and analyzed 230 studies from 22 countries: 34 randomized...Read more


CooperCompanies Announces Fourth Quarter and Full Year 2024 Results

December 5
Last Trade: 93.44 1.51 1.64

SAN RAMON, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced financial results for its fiscal fourth quarter and full year ended October 31, 2024. Fourth quarter 2024 revenue of $1,018.4 million, up 10%, or up 7% organically. Fiscal year 2024 revenue of $3.9 billion, up 8%, or up 8% organically. Fourth quarter 2024 GAAP diluted earnings per share...Read more


Zynex Announces Completion of Its Laser Pulse Oximetry Trial

December 5
Last Trade: 8.25 -0.15 -1.79

ENGLEWOOD, Colo., Dec. 5, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it has completed its clinical verification trial for their NiCO™ pulse oximeter overseen by anesthesiologist Dr. David...Read more


LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting

December 5
Last Trade: 47.59 0.10 0.21

LONDON / Dec 05, 2024 / Business Wire / LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its participation in the American Epilepsy Society (AES) 2024 Annual Meeting, taking place December 6-10 in Los Angeles. The Company’s therapies and technologies for drug-resistant epilepsy treatment will be featured in numerous scientific posters to support a deeper understanding of the non-pharmacological...Read more


Hyperfine Announces Extensive Clinical Study Coverage at RSNA 2024, Showcasing the Body of Evidence Supporting the Use of the Swoop® System Across Different Sites of Care

December 5
Last Trade: 0.89 -0.05 -4.84

Eleven clinical studies presented at RSNA 2024 highlighted the growing clinician experience with the Swoop® system for imaging diverse patient groups in emergency departments and neuro ICUs. GUILFORD, Conn. / Dec 05, 2024 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging...Read more


IceCure Medical's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results

December 5
Last Trade: 1.12 -0.04 -3.04

Data confirm previous results showing that ProSense® cryoablation is highly effective for kidney tumors < 3 cm and a safe procedure for kidney tumors < 5 cm in people ineligible for surgery Interim results presented at the Israeli Urological Association Conference in Eilat, Israel ProSense® is approved for benign and malignant kidney tumors in the U.S., Europe and numerous other countries CAESAREA, Israel, Dec. 5, 2024...Read more


OrthoPediatrics Expands Specialty Bracing Portfolio with Two New Products

December 5
Last Trade: 22.38 -0.21 -0.93

WARSAW, Ind., Dec. 05, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics today announced that the OrthoPediatrics Specialty Bracing (OPSB™) division is expanding its product offering with the launch of two new products including the OPSB Sensor System and MOVE-D™. The OPSB Sensor System represents the first...Read more


Theralase Technologies Launches New Clinical Study Site in Canada

December 5
Last Trade: 0.25 -0.02 -7.41

St. Joseph's Healthcare Hamilton is the latest Canadian clinical study site for clinical investigation of Theralase®'s Anti-Cancer Therapy for the treatment of bladder cancer TORONTO, ON / ACCESSWIRE / December 5, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or...Read more


Nano-X Imaging.ARC Imaging System Receives FDA Clearance for General Use, Including Pulmonary Indication

December 5
Last Trade: 6.76 0.19 2.89

Nanox.ARC receives additional FDA clearance to produce tomographic images for general use, including pulmonary, intra-abdominal and paranasal indications, in addition to its previously cleared indication for the musculoskeletal system Nanox.ARC uses high voltage powered digital X-ray tubes for 3D tomosynthesis imaging that could help expand availability of medical imaging Nanox.ARC now deployed at healthcare facilities across seven...Read more


Profound Medical Announces Proposed Public Offering of Common Shares

December 5
Last Trade: 7.25 -0.03 -0.41

BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced that it intends to offer and sell common shares (the “Common Shares”) in an underwritten public offering (the “Offering”). In addition, Profound expects to grant the...Read more


Treace Medical Concepts Announces First Cases Utilizing RedPoint™ Intelliguide™ Patient Specific Instrumentation with the Adductoplasty® System for Correction of Midfoot Deformities

December 4
Last Trade: 6.96 0.06 0.87

PONTE VEDRA, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the successful completion of the first cases combining IntelliGuide™ PSI technology with the Adductoplasty®...Read more


NeuroPace to Showcase the RNS System at the 2024 American Epilepsy Society (AES) Annual Meeting

December 4
Last Trade: 11.53 0.39 3.50

RNS System to be featured in over 70 scientific presentations and posters Pre-book a demonstration in the NeuroPace Tech Suite to see the latest innovations of the RNS System which simplify the treatment experience for physicians and patients NeuroPace’s Booth #2119 MOUNTAIN VIEW, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- December 4, 2024 – NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives...Read more


Milestone Scientific to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference on December 11th, 2024

December 4
Last Trade: 0.93 0.13 16.05

ROSELAND, N.J., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that its CEO Arjan Haverhals and Chairman Neal Goldman will be presenting at The Benchmark Company’s 13th Annual Discovery One-on-One Investor Conference to be held Wednesday, December 11th, 2024 at the New York Athletic...Read more


Sign Up To Get Daily Life Science Stock News

Please review our Disclaimer and Privacy Policy before subscribing.

Medical Device Gainers

 
CompanyChangeLast Trade
Insulet 10.01 3.90 $266.57
Stryker 7.46 2.09 $364.60
Glaukos 7.14 4.97 $150.88
ResMed 5.69 2.46 $237.27
West Pharmaceutical 4.39 1.34 $331.40
Becton Dickinson 3.85 1.72 $227.68
ICU Medical 3.62 2.36 $156.82
Teleflex 3.37 1.93 $178.16
STERIS 3.15 1.54 $207.49
iRhythm Technologies 2.73 3.11 $90.39
Tandem Diabetes Care 2.64 7.94 $35.91
Movano Health 2.54 81.67 $5.65
Pro-Dex 2.39 5.16 $48.74
Inspire Medical Systems 2.35 1.27 $187.77
Sanara MedTech 2.09 6.62 $33.68

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

COPYRIGHT ©2023 HEALTH STOCKS HUB